His Testosterone Came Back at 240. Here's What Happened Next.

Why It Matters

Misguided testosterone prescriptions waste resources and can harm patients, underscoring the need for evidence‑based, whole‑person evaluation in the booming wellness market.

Key Takeaways

• Low testosterone diagnosis often misinterpreted as sole cause of fatigue.
• Clinics may treat lab numbers, not underlying health issues.
• Testosterone levels can be suppressed by lifestyle, stress, and obesity.
• Evidence shows hormone therapy can worsen symptoms without proper assessment.
• Comprehensive evaluation needed before prescribing testosterone injections to patients.

Summary

The Barbell Medicine podcast opens with a cautionary case study from the forthcoming book *Signal*: a 45‑year‑old architectural partner named Mark experiences a dramatic drop in focus, energy, and marital stability, prompting a wellness clinic to test his hormone panel. The results show a total testosterone of 240 ng/dL, a figure the clinic interprets as the root cause and immediately treats with weekly testosterone injections.

Over the next three months, Mark’s condition deteriorates—fatigue intensifies, headaches emerge, and his blood pressure climbs. The host, Dr. Jordan Feigenbaum, argues that the clinic’s protocol fixated on a single lab value rather than a comprehensive health assessment. He points out that low testosterone often reflects broader issues such as chronic stress, poor sleep, obesity, and metabolic dysfunction, which the clinic ignored.

Feigenbaum emphasizes that the “testosterone crisis” narrative can be misleading when clinicians prescribe hormones without confirming true hypogonadism. He cites emerging research indicating that indiscriminate testosterone therapy may exacerbate cardiovascular risk and fail to improve energy or cognition unless the underlying drivers are addressed.

The broader implication for the health‑tech and wellness industry is clear: providers must prioritize holistic diagnostics and lifestyle interventions before resorting to hormone replacement. For employers and insurers, the lesson is to scrutinize testosterone‑related claims and ensure that treatment pathways are evidence‑based, protecting both patient outcomes and cost efficiency.

Original Description

A 45-year-old architect walks into a wellness clinic. Two days later, the number comes back: total testosterone 240. He starts TRT — and by month three, he feels worse than before.

This is the opening story from Episode 1 of the Signal launch series on the Barbell Medicine Podcast. Two physicians break down what went wrong and why the clinic treated the number instead of the patient.

Full episode live on April 14: https://www.youtube.com/watch?v=dm5FxIw-I7Y&feature=youtu.be

#testosterone #TRT #lowt #testosteronelevels #barbellmedicine #signal